U.S. Senate Approves Measure to Support Operations at the FDA to Help Propel Bioscience & MedTech Investment and Innovation
Sponsored by CLSA, AB 602 Protects Patients with Diabetes from Counterfeit or Improperly Sold Diabetes Test Devices
As California’s legislature heads into its break for the summer, returning on Aug. 21, the top three bills of concern to the life sciences industry all face the potential for amendments before reaching their respective final floor votes.
Update on Key CLSA Federal Policy Activities in Washington, D.C.
On July 14, 2017, CLSA partnered with Organovo, Takeda and Sanford Burnham Prebys to host a tour for members of the California Legislative Technology and Innovation Caucus.
CLSA’s Brett Johnson provides analysis to the San Francisco Business Times on three major bills (SB 790, SB 17 and AB 215) the life sciences sector is facing in Sacramento.
California policymakers are considering legislation (SB 790) that would restrict the California life sciences sector’s ability to provide continuing education to physicians and discuss the clinical benefits of medicines.
CLSA was recently featured in BOSS Magazine regarding our efforts to drive solution-oriented public policies and advocacy activities that sustain and support life sciences research, investment and innovation in California. View the executive profile for more.
On June 13, CLSA hosted a roundtable discussion with Los Angeles Mayor Eric Garcetti, CLSA Board Members and other life sciences sector executives from the region to discuss life sciences innovation, investment and job creation.
On June 27, two bills with significant negative consequences for the life sciences industry, Senate Bill 17 (Hernandez) and SB 790 (McGuire), were passed out of California’s Assembly Health Committee.